The company has registered total income of Rs. 3,847 crores for Q4 FY21, up by 3% on a y-o-y basis from Rs. 3,752 crores registered during corresponding period of the previous year
Jubilant successfully challenged Bracco's patent infringement claims in an Inter Parties Review (IPR) proceeding before the U.S. Patent Office
Molnupiravir is an investigational oral antiviral drug currently being studied in a Phase 3 trial for the treatment of non-hospitalized patients with confirmed COVID-19
GSKP announced sale of its newly constructed manufacturing plant at Vemgal, Karnataka to Hetero Labs for a cash consideration of Rs1.8bn
AdCOVID is a COVID-19 vaccine candidate that is administered via nasal spray.
ranules now has a total of 38 ANDA approvals from US FDA.
Subscribe To Our Newsletter & Stay Updated
